Antimicrobial activities of cinnamyl rifamycin derivatives, T-9 and T-11, against Mycobacterium tuberculosis and Mycobacterium avium complex (MAC) with special reference to the activities against intracellular MAC

Microbiology and Immunology

Volumn 50, Issue 8, 2006, Pages 621-623

  Sato, Katsumasa ^a   Shimizu, Toshiaki ^a   Dimova, Velitchka ^b   Tomioka, Haruaki ^a  

^a SHIMANE UNIVERSITY   (Japan)

^b NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES   (Bulgaria)

Author keywords

Antimycobacterial activity; Macrophages; Mycobacterium avium complex; Mycobacterium tuberculosis

Indexed keywords

RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAMYCIN DERIVATIVE;

ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; LUNG ALVEOLUS CELL TYPE 2; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM COMPLEX (MAC); MYCOBACTERIUM TUBERCULOSIS;

EID: 33747854632     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2006.tb03836.x     Document Type: Article

References (15)

1. Barrow, W.W. 2004. Microsphere technology for chemotherapy of mycobacterial infections. Curr. Pharm. Des. 10: 3275-3284.
2. Barry, C.E., 3rd, Boshoff, H.I., and Dowd, C.S. 2004. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr. Pharm. Des. 10: 3239-3262.
3. Blanc, D.C., Nunn, P., and Duncan. K. 2000. Incentives and disincentives for new anti-tuberculous drug development. Situational analysis, p. 1-59. World Health Organization.
4. Blomberg, B., Spinaci, S., Fourie, B., and Laing. R. 2001. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull. World Health Organ. 79: 61-68.
5. Dimova, V., Stefanova, P., and Valova, N. 1993. Pharmacokinetic studies in experimental animals on cinamyl rifamycin derivative (T-9), p. 351-352. In Advances in chemotherapy, Proceedings of the 17th International Congress of Chemotherapy, Stockholm.
6. Reddy, V.M., Nadadhur, G., Daneluzzi, D., Dimova, V., and Gangadharam, P.R. 1995. Antimycobacterial activity of a new rifamycin derivative, 3-(4-cinnamylpiperazinyl iminomethyl) rifamycin SV (T9). Antimicrob. Agents Chemother. 39: 2320-2324.
7. Schraufnagel, D.E. 1999. Tuberculosis treatment for the beginning of the next century. Int. J. Tuberc. Lung Dis. 3: 651-662.
8. Skinner, M.H., and Blashke, T.F. 1995. Clinical pharmacokinetics of rifabutin. Clin. Pharmacokinet. 28:115-125.
9. Temple, M.E., and Nahata, M.C. 1999. Rifapentine: its role in the treatment of tuberculosis. Ann. Pharmacother. 33:1203-1210.
10. Tomioka, H. 2004. Present status and future prospects of chemotherapeutics for intractable infections due to Mycobacterium avium complex. Curr. Drug Discovery Technol. 1: 255-268.
11. Tomioka, H. 2005. Development of new antituberculous drugs: strategies for new drug targets and drug delivery. Drug Design Rev. 2: 427-434.
12. Tomioka, H. 2006. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities. Curr. Pharm. Des. in press.
13. Tomioka, H., Sato, K., Sano, C., Sano, K., and Shimizu, T. 2002. Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells. Antimicrob. Agents Chemother. 46: 519-521.
14. Wagner, D., and Young, L.S. 2004. Nontuberculous mycobacterial infections: a clinical review. Infection 32: 257-270.
15. Yamane, T., Hashizume, T., Yamashita, K., Konishi, E., Hosoe, K., Hidaka, T., Watanabe, K., Kawaharada, H., Yamamoto, T., and Kuze, F. 1993. Synthesis and biological activity of 3′-hydroxy-5′-aminobenzoxazinorifamycin derivatives. Chem. Pharm. Bull. (Tokyo) 41: 148-155.